Biologics CDMO
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
395
NCT05731752
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: May 28, 2020
Completion: Dec 30, 2024
NCT05731934
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Start: Sep 15, 2020
Completion: Jan 12, 2024
NCT05189093
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Phase: Phase 1/2
Start: Dec 31, 2021
Completion: Dec 31, 2026
NCT06703255
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Start: Jan 8, 2025
Completion: Dec 31, 2028
NCT06708663
HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours
Start: Jan 17, 2025
Loading map...